| Literature DB >> 34276670 |
Wenran Zhang1, Zhaoyang Tang1, Yanjun Shi2, Long Ji1, Xueyu Chen1, Yanru Chen1, Xiaohui Wang1, Meng Wang1, Wei Wang1, Dong Li1,3.
Abstract
Background: Systemic lupus erythematosus (SLE) affects many organs and systems of the human organism, at present, its specific pathogenesis is not completely clear, but inflammation is considered to be an important factor involved in the pathogenesis and progression of SLE. Gamma-glutamyl transpeptidase (GGT) and total bilirubin (TBIL) have different effects on inflammation: GGT has pro-inflammatory effects, on the contrary, TBIL has anti-inflammatory effects. Study has found that GGT and TBIL play opposite roles in metabolic diseases. However, the roles of them in SLE are unknown. Meanwhile, the relationship between GGT and SLE also remains unexplored. Method: We recruited 341 SLE patients and 332 healthy individuals in Liaocheng People's Hospital from August 2018 to May 2019. We diagnosed SLE using 2019 revised American College of Rheumatology (ACR) SLE criteria, and modeled the study outcomes using logistic regression to explore the respective relationship between GGT, TBIL and SLE. We also analyzed the interaction of GGT and TBIL in the progression of SLE.Entities:
Keywords: case-control study; diagnostic marker; female population; gamma-glutamyl transferase; systemic lupus erythematosus; total bilirubin
Year: 2021 PMID: 34276670 PMCID: PMC8277571 DOI: 10.3389/fimmu.2021.682400
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 7.561
Baseline characteristics.
| Characteristic | SLE | Control | P | ||
|---|---|---|---|---|---|
| Total (N=341) | Unaggravated Group (N=201) | Aggravated Group (N=140) | (N=332) | ||
| Age (mean ± SD) | 40.46 ± 12.92 | 40.71 ± 0.77 | 39.09 ± 1.66 | 49.10 ± 12.07 | <0.001 |
| GGT (U/L) | 20.00 (14.00,31.00) | 17.00 (13.00,27.00) | 23.00 (13.00,42.00) | 16.00 (12.25,22.75) | <0.001 |
| TBIL (mg/L) | 10.90 (8.30,13.80) | 11.50 (8.52,14.97) | 10.35 (8.10,12.70) | 13.10 (10.50,16.70) | <0.001 |
| ALT(U/L) | 23.00 (17.00,30.00) | 15.00 (12.00,21.00) | 22.00 (17.00,29.75) | 27.00 (12.00,32.00) | <0.001 |
| AST(U/L) | 22.00 (20.00,27.00) | 23.00 (20.00,27.00) | 21.00 (17.25,26.75) | 23.00 (16.00,28.00) | 0.652 |
| SUA (umol/L) | 257.00 (194.50,306.00) | 269.00 (199.00,315.00) | 233.00 (188.25,281.75) | 295.00 (237.25,352.00) | <0.001 |
| Menopause (n, %) | 104 (30.50) | 85 (42.28) | 19 (13.57) | 81 (24.40) | 0.076 |
| Current smoker (n, %) | 8 (2.34) | 4 (0.19) | 4 (2.85) | 3 (0.09) | 0.141 |
| Mild-moderate drinking (n, %) | 57 (16.71) | 43 (21.39) | 14 (10.00) | 5 (1.51) | <0.001 |
| BMI (mean ± SD) | 23.92 ± 3.15 | 23.98 ± 0.19 | 23.62 ± 0.35 | 23.65 ± 2.75 | 0.244 |
| Hypertension (n, %) | 33 (9.68) | 26 (12.93) | 7 (5.00) | 12 (3.61) | <0.001 |
| TC (mmol/L) | 4.56 (3.78,5.63) | 4.58 (3.80,5.70) | 4.52 (3.57,5.30) | 5.08 (4.40,5.74) | <0.001 |
| TG (mmol/L) | 1.27 (0.91,1.81) | 1.31 (0.96,1.79) | 1.21 (0.81,1.90) | 1.19 (0.80,1.81) | 0.225 |
| HDL (mmol/L) | 1.24 (1.04,1.56) | 1.23 (1.04,1.55) | 1.27 (1.01,1.57) | 1.48 (1.27,1.72) | <0.001 |
| LDL (mmol/L) | 2.81 (1.71,3.91) | 2.64 (2.02,3.69) | 2.54 (1.78,2.97) | 2.04 (1.42,2.66) | <0.001 |
| GLU (mmol/L) | 5.64 (3.83,7.45) | 5.18 (4.75,5.90) | 5.23 (4.79,6.02) | 5.77 (4.47,7.07) | <0.001 |
Unaggravated Group: SLEDAI Score < 10 and involved the skin, mucous membranes or joints.
Aggravated Group: SLEDAI Score > 10 and involved the kidneys, lungs, or cardiovascular system.
Inflammatory and Immunological index in SLE patients.
| Characteristic | SLE | GGT | TBIL | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Total | Unaggravated Group | Aggravated Group |
| rs |
| rs |
| ||
| Inflammatory index | CRP (mg/L) | 8.64 (3.41,19.83) | 7.75 (3.22,15.23) | 10.21 (3.68,41.27) | 0.034* | 0.417 | <0.001* | -0.328 | <0.001* |
| IL-2 (pg/mL) | 0.30 (0.10,0.63) | 0.22 (0.10,0.50) | 0.33 (0.10,0.66) | 0.063 | 0.022 | 0.686 | 0.075 | 0.169 | |
| IL-4 (pg/mL) | 0.20 (0.10,0.50) | 0.20 (0.10,0.52) | 0.25 (0.10,0.47) | 0.231 | 0.039 | 0.47 | 0.039 | 0.478 | |
| IL-6 (pg/mL) | 23.42 (11.39,63.09) | 19.1 (10.08,49.08) | 32.97 (15.95,111.52) | <0.001* | 0.412 | <0.001* | 0.015 | 0.779 | |
| IL-10 (pg/mL) | 2.61 (1.08,5.52) | 2.61 (1.21,5.36) | 2.76 (0.99,5.84) | 0.879 | 0.015 | 0.786 | -0.054 | 0.316 | |
| TNF-α (pg/mL) | 15.79 (11.00,32.76) | 13.8 (10.17,24.96) | 20.14 (12.25,41.72) | <0.001* | 0.001 | 0.98 | -0.36 | <0.001* | |
| IgG (mg/L) | 15.30 (12.00,19.35) | 15.30 (12.30,19.75) | 15.20 (11.80,19.22) | 0.459 | -0.075 | 0.166 | 0.01 | 0.848 | |
| IgA (mg/L) | 2.71 (1.88,3.58) | 2.74 (1.95,3.58) | 2.69 (1.74,3.58) | 0.678 | -0.068 | 0.211 | 0.03 | 0.586 | |
| IgM (mg/L) | 0.90 (0.60,1.31) | 0.93 (0.61,1.31) | 0.85 (0.58,1.31) | 0.684 | -0.041 | 0.45 | 0.013 | 0.807 | |
| Immunological Index | C3 (g/L) | 0.66 (0.41,0.87) | 0.70 (0.53,0.93) | 0.53 (0.36,0.74) | <0.001* | -0.177 | <0.001* | 0.174 | 0.001* |
| C4 (g/L) | 0.13 (0.08,0.21) | 0.14 (0.10,0.23) | 0.12 (0.08,0.16) | 0.001* | -0.132 | 0.015* | 0.172 | 0.001* | |
| Positive of anti-SM (n, %) | 145 (42.52) | 81 (40.29) | 64 (45.71) | 0.32 | -0.009 | 0.864 | -0.001 | 0.982 | |
| Positive of anti-SSA (n, %) | 212 (62.17) | 115 (57.21) | 97 (69.28) | 0.024* | -0.011 | 0.87 | 0.02 | 0.716 | |
| Positive of anti-SSB (n, %) | 61 (17.88) | 30 (14.92) | 31 (22.14) | 0.087 | -0.074 | 0.174 | 0.018 | 0.739 | |
| Positive of anti-dsDNA (n, %) | 174 (51.02) | 109 (54.23) | 65 (46.42) | 0.156 | -0.127 | 0.019* | 0.011 | 0.839 | |
| Positive of anti-RNP (n, %) | 103 (30.21) | 59 (29.35) | 44 (31.42) | 0.681 | 0.019 | 0.732 | 0.022 | 0.69 | |
| SLEDAI | 8 (3,12) | 5 (3,8) | 12 (10,15) | <0.001* | 0.188 | <0.001* | -0.121 | 0.026* | |
*P < 0.05.
Figure 1Association of TBIL, GGT and aggravation of SLE in patients. Model 1: unadjusted. Model 2: adjusted for age, BMI, smoking status, alcohol consumption and estrogen level. Model 3: adjusted for age, BMI, smoking status, alcohol consumption, estrogen level, ALT, AST, SUA, CRP, IL-2, IL-4, IL-6, IL-10, TNF-α, hypertension, hyperlipidemia and diabetes mellitus. GGT: Q1, quartile 1 (n=89): ≤14 U/L; Q2, quartile 2 (n=88): 15-20 U/L; Q3, quartile 3 (n=82): 21-31 U/L; Q4, quartile 4 (n=82): >31 U/L. TBIL: Q1, quartile 1 (n=90): ≤8.3 mg/L; Q2, quartile 2 (n=83): 8.4-10.9 mg/L; Q3, quartile 3 (n=84): 11.0-13.8 mg/L; Q4, quartile 4 (n=84): >13.8 mg/L.
Figure 2Interaction between TBIL and GGT in aggravation of SLE in patients. Model 1: unadjusted. Model 2: adjusted for age, BMI, smoking status, alcohol consumption and estrogen level. Model 3: adjusted for age, BMI, smoking status, alcohol consumption, estrogen level, ALT, AST, SUA, CRP, IL-2, IL-4, IL-6, IL-10, TNF-α, hypertension, hyperlipidemia and diabetes mellitus.
Figure 3ROC curve of TBIL, GGT and the combined effect in development of SLE.